Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947083 · ClinicalTrials.gov registry record · Phase 2
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
A Phase 2 study of Myeloma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06947083 is a Phase 2 study of Myeloma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 39 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06947083, a Phase 2 study of Myeloma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2029-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06947083
The ClinicalTrials.gov registry entry for NCT06947083 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (60% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.
NCT06947083 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06947083 about?
NCT06947083 is a clinical study titled "Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma". The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, define...
What is the current status of trial NCT06947083?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2025-05-27. Estimated completion is 2029-04.
What conditions does trial NCT06947083 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT06947083?
The interventions under investigation include: Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06947083?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947083 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.